drugset / Trial / NCT01127893
Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
An evaluation of the long term safety of tanezumab when administered by subcutaneous injection every 8 weeks for up to 64 weeks
Timeline
- Start
- 2010-06-15
- Primary completion
- 2010-09-29
- Completion
- 2010-09-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tanezumab | Monoclonal antibody | 2.5 mg | Subcutaneous |
| Subject | Tanezumab | Monoclonal antibody | 5 mg | Subcutaneous |
| Subject | Tanezumab | Monoclonal antibody | 10 mg | Subcutaneous |